GREG ALLAN BLISS, M.D.

WARRENSBURG, MO

Research Active
Orthopaedic Surgery NPI registered 21+ years 14 publications 1986 – 2026 NPI: 1770588857
CaregiversQuality of LifeQualitative ResearchPhenotypeAutism Spectrum DisorderRare DiseasesGenetic Association StudiesNeurodevelopmental DisordersPatient-Centered CareCommunicationChromosome DisordersCommunication DisordersChromosome DeletionNerve Tissue ProteinsChromosomes, Human, Pair 22

Practice Location

510 FOSTER LN
WARRENSBURG, MO 64093-3239

Phone: (660) 747-2228

What does GREG BLISS research?

Dr. Bliss studies communication capabilities and the genetic underpinnings of rare neurodevelopmental disorders, primarily focusing on Phelan-McDermid syndrome, a condition that can lead to developmental delays and various physical issues. His research involves gathering insights from caregivers about how these children interact and express themselves, as well as analyzing genetic data to understand how variations can impact the severity of symptoms. Through these efforts, he aims to inform better treatment approaches and diagnostic tools for affected individuals.

Key findings

  • In his study of communication abilities, Dr. Bliss conducted 115 interviews with caregivers and found that children communicate complex ideas like feelings and humor, beyond just basic needs.
  • His research on Phelan-McDermid syndrome, analyzing data from 401 individuals, showed that larger genetic deletions are linked to more severe developmental delays and associated issues like poor muscle tone and heart defects.
  • By integrating patient-reported outcomes with clinical notes and genetic reports in a database, he created a resource that combines information from 112 patients' clinical data and survey responses from 415 patients, aiding better understanding of Phelan-McDermid syndrome.

Frequently asked questions

Does Dr. Bliss study Phelan-McDermid syndrome?
Yes, Dr. Bliss focuses heavily on Phelan-McDermid syndrome, exploring its genetic causes and the communication abilities of affected children.
What insights has Dr. Bliss gathered from caregivers?
He has gathered important caregiver perspectives on drug development priorities, highlighting the need for treatments that enhance quality of life for individuals with Phelan-McDermid syndrome.
What types of research does Dr. Bliss conduct related to neurodevelopmental disorders?
Dr. Bliss conducts qualitative studies that explore communication methods in children with rare neurodevelopmental disorders and genetic research to understand the impact of genetic variations on symptoms.

Publications in plain English

The spectrum of communication abilities in children with 12 rare neurodevelopmental disorders: a qualitative study with caregivers.

2026

Journal of child psychology and psychiatry, and allied disciplines

Zigler CK, McFatrich M, Lucas N, Plyler K, Zapata-Leiva L +27 more

Plain English
This study looked at how children with 12 rare neurodevelopmental disorders communicate, gathering insights from their caregivers. Researchers conducted 115 interviews and found that while many children used various methods like speech, gestures, and sign language to express basic needs, they also communicated more complex ideas like feelings and humor. This research is important because it helps to improve tools for measuring communication abilities in these children, ensuring that their unique needs are understood in clinical settings. Who this helps: This helps caregivers, healthcare providers, and researchers working with children who have neurodevelopmental disorders.

PubMed

Caregiver perspectives on patient-focused drug development for Phelan-McDermid syndrome.

2024

Orphanet journal of rare diseases

Gizzo L, Bliss G, Palaty C, Kolevzon A

Plain English
This study focused on caregivers' insights regarding drug development for Phelan-McDermid syndrome (PMS), a disorder that significantly affects individuals' lives and well-being. Caregivers emphasized the need for treatments that enhance quality of life, particularly in areas like cognitive ability, communication, independence, and avoiding regressions. By sharing these perspectives, the findings aim to guide future drug development to better meet the needs of patients. Who this helps: This benefits patients with Phelan-McDermid syndrome and their families.

PubMed

A roadmap for SHANK3-related Epilepsy Research: recommendations from the 2023 strategic planning workshop.

2024

Therapeutic advances in rare disease

Savage MC, Bliss G, Buxbaum JD, Farrell JS, Levin AR +4 more

Plain English
Researchers gathered at a conference in Boston in September 2023 to discuss what is still unknown about SHANK3-related epilepsy and to set priorities for future studies. They identified key areas where more research is needed, such as understanding the clinical and preclinical aspects of this condition. This is important because better research can lead to improved treatments for those affected by this type of epilepsy. Who this helps: This benefits patients with SHANK3-related epilepsy and their families.

PubMed

Phenome-wide profiling identifies genotype-phenotype associations in Phelan-McDermid syndrome using family-sourced data from an international registry.

2024

Molecular autism

Yin R, Wack M, Hassen-Khodja C, McDuffie MT, Bliss G +8 more

Plain English
This research focused on Phelan-McDermid syndrome (PMS), a rare disorder caused by missing genetic material that affects development. Scientists analyzed data from 401 individuals, finding that larger genetic deletions were linked to more severe developmental delays and physical issues like poor muscle tone and heart defects. This matters because it helps us understand how different genetics can affect the severity of PMS symptoms, which can improve care and support for affected individuals. Who this helps: This helps patients and their families, as well as healthcare providers looking for tailored treatment approaches.

PubMed

Bringing everyone to the table - findings from the 2018 Phelan-McDermid Syndrome Foundation International Conference.

2020

Orphanet journal of rare diseases

Goodspeed K, Bliss G, Linnehan D

Plain English
The 2018 Phelan-McPosium brought together 183 families and 35 researchers to discuss Phelan-McDermid Syndrome (PMS), a rare developmental disorder. Families shared their concerns, which varied by the age of their affected loved ones: parents of young children were less worried, while families of teens and adults focused on genetic testing, seizures, and gastrointestinal issues. This gathering helped frame important research questions that could improve treatments for PMS, benefiting future care standards. Who this helps: Patients and their families affected by Phelan-McDermid Syndrome.

PubMed

Phelan-McDermid syndrome data network: Integrating patient reported outcomes with clinical notes and curated genetic reports.

2018

American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics

Kothari C, Wack M, Hassen-Khodja C, Finan S, Savova G +8 more

Plain English
This study focused on creating a platform called the Phelan-McDermid Syndrome Data Network (PMS_DN) to improve research on Phelan-McDermid Syndrome (PMS), a rare genetic disorder linked to autism and intellectual disabilities. The network combines data from 112 patients' clinical notes, genetic reports from 176 patients, and survey data from 415 patients to provide a comprehensive view of the disorder, which will help researchers understand its causes and progression. This is important because it makes valuable patient information more accessible and can drive better research into this rare condition. Who this helps: This helps patients with Phelan-McDermid Syndrome and their families by promoting research that may lead to improved treatments and understanding of their condition.

PubMed

Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

2015

Clinical trials (London, England)

Lantos JD, Wendler D, Septimus E, Wahba S, Madigan R +1 more

Plain English
This study looked at how risk is assessed in pragmatic clinical trials, which compare common medical treatments used in everyday healthcare. Researchers found that there is a lot of confusion about what constitutes "minimal risk," which can lead to delays in important research that might help patients. They argue for clearer guidelines to differentiate between the inherent risks of treatments and the additional risks from participating in the research itself. Who this helps: This helps patients and researchers by enabling quicker access to potentially beneficial treatments through better-defined study regulations.

PubMed

Practice profile. A direct primary care medical home: the Qliance experience.

2010

Health affairs (Project Hope)

Wu WN, Bliss G, Bliss EB, Green LA

PubMed

Equine's Cushing's Disease: A Clinical Update.

2007

International journal of pharmaceutical compounding

Bliss G

Plain English
Researchers at North Carolina State University are studying ways to treat Cushing's disease in horses using a medication called pergolide. Their review of existing literature highlights several treatment options and helps explain how the disease affects horses. Understanding these treatments and the disease's mechanisms is important for improving the health and quality of life for horses with Cushing's disease. Who this helps: This helps horse owners and veterinarians.

PubMed

Let the beauty of the marketplace benefit healthcare.

2006

The Journal of the American Osteopathic Association

Bliss G

PubMed

The Carmarthen audit project.

1994

Journal of nursing management

Bliss G, Martin P

Plain English
This study focused on improving the way mental health services in East Dyfed measure their own quality of care using a new audit process. The researchers found that when clinical staff take charge of these evaluations, they are more invested in improving services. This is important because it helps ensure that patients receive better care that meets established standards. Who this helps: This helps patients and mental health professionals.

PubMed

B.C. facility pioneers 'case-mix' cost tracking.

1989

Health care

Bliss G

PubMed

Tear film stability and tear surface tension.

1989

Current eye research

Tiffany JM, Winter N, Bliss G

Plain English
This study looked at the stability of tear films and their surface tension in people with normal tears compared to those with dry eyes. Researchers found that the average surface tension of tears is higher in dry eyes (49.6) than in normal eyes (43.6), and that dry eyes had a much shorter tear break-up time, with an average of just 8.9 seconds compared to over 30 seconds for normal eyes. Understanding these differences helps better classify and manage dry eye conditions, making it easier to treat patients effectively. Who this helps: This helps patients experiencing dry eye symptoms.

PubMed

The effectiveness of therapy in improving finger extension in stroke patients.

1986

The American journal of occupational therapy : official publication of the American Occupational Therapy Association

Trombly CA, Thayer-Nason L, Bliss G, Girard CA, Lyrist LA +1 more

Plain English
This study looked at how different types of exercises help stroke patients improve their finger movement. Researchers found that patients who practiced certain exercises, like ballistic and resisted extension, were better at quickly moving their fingers compared to those who did not do these exercises. However, the overall improvement in finger movement was not significantly better than the control group, suggesting that simply using different exercises may not be enough to enhance function for all stroke patients. Who this helps: This research helps stroke patients seeking ways to regain finger movement.

PubMed

Frequent Co-Authors

Maxime Wack Claire Hassen-Khodja Elizabeth J Horn Cartik Kothari Rebecca Davis Megan O'Boyle Paul Avillach Christina K Zigler Molly McFatrich Nicole Lucas

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.